TrialJournal of cancer research and clinical oncology2022
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Sabine Kürzel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.